OPEN ENROLLMENT
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
The purpose of this study is to determine if the investigational study drug, XL092, in combination with nivolumab is effective in treating unresectable, locally advanced or metastatic non-clear renal…
- Investigator
- Kethandapatti Balaji
- IRB Number
- XL092-304
- Ages
- 18 Years – 100 Years
- Sexes
- All
- Location
- Jacksonville
OPEN ENROLLMENT
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC who are BCG Naïve/Received Incomplete BCG Treatment
This study will evaluate the safety and tolerability of EG-70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors…
- Investigator
- Kethandapatti Balaji
- IRB Number
- EG-70-101
- Ages
- 18 Years – 100 Years
- Sexes
- All
- Location
- Jacksonville
OPEN ENROLLMENT
BCG in combination with durvalumab in adult BCG-naive, high-risk NMIBC participants
The PATAPSCO study will explore the combination of durvalumab and BCG (induction and maintenance) in BCG-naïve participants with high-risk NMIBC. This combination may thus provide the dual…
- Investigator
- Kethandapatti Balaji
- IRB Number
- D419jC00002
- Ages
- 18 Years – 99 Years
- Sexes
- All
- Location
- Jacksonville
OPEN ENROLLMENT
Study of BD ORC Original Absorbable Hemostat Compared with Surgicel® Original Absorbable Hemostat
The purpose of this study is to evaluate the safety and efficacy of BD ORC Original Absorbable Hemostat when compared to a currently marketed ORC hemostat (Surgicel® Original Absorbable Hemostat)…
- Investigator
- Kethandapatti Balaji
- IRB Number
- DVL-HEM-001
- Ages
- 22 Years – 101 Years
- Sexes
- All
- Location
- Jacksonville
OPEN ENROLLMENT
A Phase 1 Study of EG-70 as an Intravesical Administration to Patients with BCG -Unresponsive NMIBC
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG -Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG…
- Investigator
- Mark Bandyk
- IRB Number
- EG-70-101
- Ages
- 18 Years – 101 Years
- Sexes
- All
- Location
- Jacksonville